首页膀胱肿瘤治疗及预后证据详情

Pioglitazone and Risk of Bladder Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Studies

原文: 2017 年 发布于 J Urol 浏览量:189次

作者: Tang H. L. Shi W. L. Fu S. S. Wang T. S. Zhai S. D. Song Y. Q. Han J. L.

作者单位: Department of Urology, Lenox Hill Hospital, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, New York, United States Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Electronic address: jjue@northwell.edu. Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Miami Transplant Institute, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Department of Surgery, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Department of Urology, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Miami Transplant Institute, Jackson Memorial Hospital, University of Miami Miller School of Medicine, Miami, United States Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1007/s00345-020-03313-w

文献简介

Background: Previous studies have indicated association between GSTM1 and GSTT1 gene polymorphisms and bladder cancer susceptibility, but the results have been inconclusive. Here, we performed a meta-analysis to investigate the association between GSTM1/GSTT1 deletion polymorphisms and bladder cancer susceptibility. Methods: We searched for all studies investigating the association between GSTM1 or GSTT1 polymorphism and bladder cancer susceptibility in Pubmed, Web of Knowledge, and the Cochrane Central Search Library. A systematic review and meta-analysis were performed. Subgroup analyses were performed on different ethnicity, population-based and smoking status. Results: Our search identified 63 studies. GSTM1 null, GSTT1 null and GSTM1/GSTT1 double-null genotypes were associated with increased risk of bladder cancer (OR: 1.36 95% CI: 1.25-1.47, P<0.01; OR: 1.13 95% CI: 1.02-1.25, P<0.01; OR: 1.84 95% CI: 1.50-2.26, P<0.01). Subgroup analyses indicated that the GSTM1-null genotype was associated with increased risk of bladder cancer in Caucasians and Asians, while the GSTT1-null genotype was associated with increased risk of bladder cancer in Caucasians. The GSTM1/GSTT1 double-null genotype was associated with increased risk of bladder cancer in Caucasians, Asians, and Africans. Stratified analyses of population-based associations indicated increased bladder cancer risk associated with GSTM1-null and GSTM1/GSTT1 double-null genotypes in hospital-based and population-based studies. GSTM1 deletion was associated with increased bladder cancer risk in both smokers and nonsmokers. Non-smokers with the GSTM1/GSTT1 double-null genotype had an increased bladder cancer risk. Conclusion: This meta-analysis demonstrates that the GSTM1-null, GSTT1-null, and GSTM1/GSTT1 double-null genotypes are associated with increased bladder cancer risk.

热门文献